Pediatric Inflammatory Bowel Disease: from diagnosis to transition

作者: Charlotte de Bie

DOI:

关键词: Ulcerative colitisAttributable riskDiseaseInflammatory bowel diseaseRectumInternal medicinePathogenesisEpidemiologyMedicineGastroenterologyBiopsy

摘要: textabstractThe inflammatory bowel diseases (IBD) are chronic relapsing disorders of the gastrointestinal tract, comprising Crohn’s disease (CD), ulcerative colitis (UC), and IBD-unclassified (IBD-U). CD is characterized by a transmural and often granulomatous inflammation that can involve any part of the tract in discontinuous manner, while UC defined as condition causing continuous mucosal inflammation colon, without granulomas on biopsy, affecting rectum and variable extent colon continuity. The term IBD-U used for patients presenting with IBD restricted to specific features either or UC.2 Early-onset represents distinct entity differences type, disease location, behavior, gender preponderance, genetically attributable risk compared late-onset IBD. As adults, treatment early-onset aimed at inducing maintaining remission, but special considerations needed regarding optimal growth, pubertal development, transition period adult care. A better understanding between will eventually lead better understanding pathogenesis disease. One limitations of studying pediatric however relatively small number patients available for study at one institution, which requires ongoing collaborations many institutions. This thesis present six (inter)national multicenter studies, single-center pilot study and review, all focus unique clinical aspects IBD, thereby complementing body literature diagnosis of children

参考文章(77)
Z. Zelinkova, C. de Haar, L. de Ridder, M. J. Pierik, E. J. Kuipers, M. P. Peppelenbosch, C. J. van der Woude, High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy Alimentary Pharmacology & Therapeutics. ,vol. 33, pp. 1053- 1058 ,(2011) , 10.1111/J.1365-2036.2011.04617.X
Emma J. Breese, Colin A. Michie, Stuart W. Nicholls, Simon H. Murch, Christopher B. Williams, Paola Domizio, John A. Walker-Smith, Thomas T. Macdonald, Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease Gastroenterology. ,vol. 106, pp. 1455- 1466 ,(1994) , 10.1016/0016-5085(94)90398-0
Charlotte I de Bie, Stephan Buderus, Bhupinder K Sandhu, Lissy de Ridder, Anders Paerregaard, Gabor Veres, Jorge Amil Dias, Johanna C Escher, None, Diagnostic workup of paediatric patients with inflammatory bowel disease in Europe: results of a 5-year audit of the EUROKIDS registry. Journal of Pediatric Gastroenterology and Nutrition. ,vol. 54, pp. 374- 380 ,(2012) , 10.1097/MPG.0B013E318231D984
Jeffry A. Katz, Christian Antoni, Gregory F. Keenan, Deirdre E. Smith, Stephen J. Jacobs, Gary R. Lichtenstein, Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn's Disease and Rheumatoid Arthritis The American Journal of Gastroenterology. ,vol. 99, pp. 2385- 2392 ,(2004) , 10.1111/J.1572-0241.2004.30186.X
David M. Knight, Han Trinh, Junming Le, Scott Siegel, David Shealy, Margaret McDonough, Bernard Scallon, Maria Arevalo Moore, Jan Vilcek, Peter Daddona, John Ghrayeb, Construction and initial characterization of a mouse-human chimeric anti-TNF antibody Molecular Immunology. ,vol. 30, pp. 1443- 1453 ,(1993) , 10.1016/0161-5890(93)90106-L
Jeffrey Hyams, Thomas D. Walters, Wallace Crandall, Subra Kugathasan, Anne Griffiths, Marion Blank, Jewel Johanns, Yinghua Lang, James Markowitz, Stanley Cohen, Harland S. Winter, Gigi Veereman-Wauters, George Ferry, Robert Baldassano, Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Current Medical Research and Opinion. ,vol. 27, pp. 651- 662 ,(2011) , 10.1185/03007995.2010.547575
Severine Vermeire, Maja Noman, Gert Van Assche, Filip Baert, Kristel Van Steen, Nele Esters, Sofie Joossens, Xavier Bossuyt, Paul Rutgeerts, Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology. ,vol. 125, pp. 32- 39 ,(2003) , 10.1016/S0016-5085(03)00701-7
Faruk Hadziselimovic, Adalimumab induces and maintains remission in severe, resistant paediatric Crohn disease. Journal of Pediatric Gastroenterology and Nutrition. ,vol. 46, pp. 208- 211 ,(2008) , 10.1097/MPG.0B013E318124504B
Bert Derkx, Jan Taminiau, Sandra Radema, Arnold Stronkhorst, Cees Wortel, Guido Tytgat, Sander van Deventer, Tumour-necrosis-factor antibody treatment in Crohn's disease The Lancet. ,vol. 342, pp. 173- 174 ,(1993) , 10.1016/0140-6736(93)91375-V
Philip Kahn, Michael Weiss, Lisa F. Imundo, Deborah M. Levy, Favorable Response to High-Dose Infliximab for Refractory Childhood Uveitis Ophthalmology. ,vol. 113, pp. 860- 864 ,(2006) , 10.1016/J.OPHTHA.2006.01.005